Forte Biosciences, Inc. (NasdaqCM: FBRX)
Health Care · Biotechnology · US
$76.95
+0.04% today · +579.8% 1Y
Forte Biosciences, Inc. (NasdaqCM: FBRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.94B and employs 22 people.
Over the last twelve months the share price has gained 579.8%, trading between 10.11 and 77.20.
Tweenvest scores Forte Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
FBRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.94B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.55
- Dividend yield
- —
- Beta (5Y)
- 2.64
- 52-week high
- $77.20
- 52-week low
- $10.11
- Avg volume (3M)
- —
- Shares outstanding
- 25.19M
- Employees
- 22
- Next earnings
- —
About Forte Biosciences, Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
- ISIN
- US34962G2084
- Listed since
- Apr 13, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.16 | +0.62% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $446.73 | +0.65% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.14 | +0.95% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.69 | +1.11% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $839.98 | +1.39% |
| argenx SEENXTBR: ARGX | $63.06B | €877.40 | +1.53% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $155.66 | +12.07% |
Figures last refreshed Aug 18, 2026.